DURHAM, N.C., and BEIJING, China – April 27, 2023 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced its participation in the following investor conferences in May 2023. Details of the conferences are as follows:

 

Guosheng Securities 2023 Listed Company Conference

Investor Meetings: May 9-12, 2023

Location: Shanghai

Participants: Management team and IR

For more information, please contact your Guosheng Securities representative.

 

CICC 2023 Healthcare Investment Forum

Investor Meetings: May 16-18, 2023

Location: Shanghai

Participants: Management team and IR

For more information, please contact your CICC representative.

 

Citi APAC Healthcare Investor Conference

Investor Meetings: May 17-19, 2023

Location: Hong Kong

Participants: Management team and IR

For more information, please contact your Citi representative.

 

Citi Pan-Asia Regional Investor Conference

Investor Meetings: May 23-25, 2023

Location: Singapore

Participants: Management team and IR

For more information, please contact your Citi representative.

 

Morgan Stanley China Summit 2023

Investor Meetings: May 30-June 1, 2023

Location: Hong Kong

Participants: Management team and IR

For more information, please contact your Morgan Stanley representative.

 

 

About Brii Bio

Brii Biosciences (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world’s most common diseases where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs to develop a novel functional cure for hepatitis B viral infection (HBV) and a first-of-its-kind treatment for postpartum depression (PPD). The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.

 

Media Inquiry:
media@briibio.com

 

Investor Inquiry:
ir@briibio.com